First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Bone involvement is frequently observed in multiple myeloma (MM) patients both at diagnosis and during the course of the disease. The evaluation of biochemical markers of bone turnover could allow a dynamic evaluation of the effects of a given therapy on bone metabolism.

Methods

In the present study, markers of bone resorption [urinary free pyridinoline (PYD), deoxypyridinoline (DPYD), N-terminal telopeptide of collagen I (NTX) and C-terminal telopeptide (serum crosslaps)] and of bone formation [bone alkaline phosphatase (BAP) and osteocalcin] were evaluated at diagnosis and after induction therapy in 40 patients (23M, 17F, median age = 53.5 yr) enrolled in the ‘Bologna 2002’ clinical trial. By study design, all patients received 4 months of combined thalidomide (100 mg/d for 2 wk then 200 mg/d), dexamethasone (40 mg/d on days 1–4, 9–12, 17–20/28 on odd cycles and on days 1–4 on even cycles) and zoledronic acid (4 mg/28 d).

Results

At diagnosis, although bone resorption markers were increased in more than 40% of the patients, only NTX (P = 0.029) and crosslaps (P = 0.000) were significantly related to the extent of skeletal lesions, as assessed by X-ray. After 4 months of therapy, a significant decrease in mean (±SE) urinary NTX (52.7 ±6.9 nmol/mmol creatinine ±6.9 vs. 14 ± 1.42 nmol/mmol creatinine, P = 0.000) and serum crosslaps (6242.4 ±945 pmol/L vs. 1414.9 ± 173.8 pmol/L, P = 0.000) was observed in patients obtaining ≥partial response, at variance to what has been detected in patients showing Conclusions

Among all bone resorption markers, urinary NTX and serum crosslaps seem to be strictly related to the extent of bone involvement in MM. Combined thalidomide + dexamethasone and zoledronic acid seem to be highly effective in reducing bone resorption in sensitive patients, although the relative contribution of each drug cannot yet be determined.

Related Topics

    loading  Loading Related Articles